Insider Transactions in Q2 2021 at Bluebird Bio, Inc. (BLUE)
Insider Transaction List (Q2 2021)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 15
2021
|
Daniel Lynch Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,353
+26.12%
|
-
|
Jun 15
2021
|
John O Agwunobi |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+24.79%
|
-
|
Jun 15
2021
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+26.19%
|
-
|
Jun 15
2021
|
Ramy Ibrahim Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+36.71%
|
-
|
Jun 15
2021
|
William R. Sellers Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+31.63%
|
-
|
Jun 15
2021
|
Mark Vachon |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+31.48%
|
-
|
Jun 15
2021
|
Denice Torres Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,109
+34.67%
|
-
|
Jun 04
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
511
-1.27%
|
$15,330
$30.75 P/Share
|
Jun 01
2021
|
Thomas J Klima |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
$775,000
$31.11 P/Share
|
May 12
2021
|
Nick Leschly |
BUY
Bona fide gift
|
Indirect |
123,000
+50.0%
|
-
|
May 12
2021
|
Nick Leschly |
SELL
Bona fide gift
|
Indirect |
123,000
-72.91%
|
-
|
May 03
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
38
-0.08%
|
$1,140
$30.15 P/Share
|
May 03
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
444
-0.14%
|
$13,320
$30.15 P/Share
|
May 03
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
39
-0.08%
|
$1,170
$30.15 P/Share
|
May 03
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
29
-0.07%
|
$870
$30.15 P/Share
|
Apr 05
2021
|
David Davidson Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
42
-0.09%
|
$1,260
$30.21 P/Share
|
Apr 05
2021
|
Jason Cole Chief Strategy & Financial Off |
SELL
Open market or private sale
|
Direct |
37
-0.08%
|
$1,110
$30.21 P/Share
|
Apr 05
2021
|
Philip D Gregory Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
39
-0.08%
|
$1,170
$30.21 P/Share
|
Apr 05
2021
|
Nick Leschly |
SELL
Open market or private sale
|
Direct |
444
-0.14%
|
$13,320
$30.21 P/Share
|
Apr 05
2021
|
Andrew Obenshain President and CEO |
SELL
Open market or private sale
|
Direct |
29
-0.07%
|
$870
$30.21 P/Share
|